News

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Is CVS Health Corporation (CVS) the Best Performing Healthcare Stock to Buy Now?
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other best ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
EconoTimes2h
Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
Is Novo Nordisk (NVO) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...